Overview

The World Health Organization (WHO) declared the Ebola outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo and Uganda as a Public Health Emergency of International Concern (PHEIC). This is a critical development as there is currently no licensed vaccine or specific therapeutic available for Bundibugyo virus disease (BVD), exposing a major gap in global vaccine preparedness.

About Bundibugyo Virus

Classification:

  • Bundibugyo virus is one of the species of the Orthoebolavirus genus that causes Ebola Virus Disease (EVD)
  • It is a zoonotic disease with fruit bats considered the most likely natural reservoir

Transmission:

  • Human infection occurs through direct contact with infected wildlife (bats and non-human primates)
  • Further spreads through contact with blood, bodily fluids, secretions, or contaminated surfaces
  • High transmission risk in healthcare settings with weak infection prevention measures
  • Transmission risk is also high during unsafe burial practices

Incubation Period:

  • Ranges from 2 to 21 days
  • Infected individuals become contagious only after onset of symptoms

Symptoms:

  • Early symptoms are non-specific: fever, fatigue, headache, muscle pain, and sore throat
  • Initial symptoms make diagnosis difficult
  • Disease progression leads to gastrointestinal complications, organ failure, and hemorrhagic symptoms

Case Fatality Rate:

  • Past outbreaks (2007 and 2012) in Uganda and DRC reported fatality rates ranging from 30% to 50%

Diagnosis Challenges:

  • BVD closely resembles other endemic febrile illnesses like malaria
  • Laboratory confirmation is essential
  • Detection through PCR testing and antigen or antibody-based diagnostic assays

Control Measures:

  • No approved vaccines or specific treatments available
  • Containment relies on rapid case detection, isolation, and supportive care
  • Contact tracing and safe burial practices
  • Strong community awareness and engagement

What is Ebola Disease?

Overview:

  • Ebola is a rare but highly severe viral illness often fatal in humans
  • Caused by viruses of the Orthoebolavirus genus
  • First identified in 1976 near the Ebola River in the Democratic Republic of Congo

Types of Orthoebolaviruses causing human illness:

  1. Ebola virus
  2. Sudan virus
  3. Bundibugyo virus (Orthoebolavirus bundibugyoense)
  4. Taï Forest virus (Orthoebolavirus taiense)

Types that have not caused human disease:

  • Reston virus
  • Bombali virus

Transmission of Ebola:

  • Direct contact with blood, body fluids, or contaminated objects of an infected person
  • Contact with infected wild animals (bats or monkeys)
  • Health workers and people involved in unsafe burial practices are at high risk

Treatment:

  • No universal cure exists
  • Treatment focuses on supportive care (rehydration and symptom management)
  • Early medical intervention significantly improves survival chances
  • WHO-approved monoclonal antibody therapies: Ansuvimab and Inmazeb

Vaccines:

  • Approved vaccines available only for Ebola virus disease
  • Major vaccines: Ervebo, Zabdeno, and Mvabea
  • Used during outbreaks and for frontline workers
  • Vaccines for Sudan virus disease and other Ebola variants still under development

Public Health Emergency of International Concern (PHEIC)

  • WHO's highest-level alert under International Health Regulations
  • Declared for serious cross-border health threats
  • Requires coordinated international response

Biosafety Level 4 (BSL-4) Laboratories

  • Required to safely study highly dangerous pathogens like ebolavirus
  • Essential when there is no widely available treatment or vaccine
  • Highest level of biosafety for handling dangerous pathogens

Why are Ebola Vaccines Difficult to Develop?

  • Outbreaks are sporadic and unpredictable
  • Different ebolavirus species require species-specific research
  • Commercial incentives are weak due to limited market
  • Research and development costs are high
  • Regulatory pathways are complex